Positive 52-week maintenance data observed with rademikibart in patients with moderate-to-severe atopic dermatitis (S<underline>EASI</underline>DE CHINA)

被引：0
|
作者：
Zhang, Jianzhong [1 ]
Silverberg, Jonathan, I [2 ]
Guo, Jiawang [3 ]
Yun, Jili [3 ]
Pan, Wuban [3 ]
Wei, Zheng [4 ]
Collazo, Raul [4 ]
机构：
[1] Peking Univ, Dept Dermatol, Peoples Hosp, Beijing, Peoples R China
[2] George Washington Univ, Sch Med & Hlth Sci, Dept Dermatol, Washington, DC USA
[3] Suzhou Connect Biopharmaceut Ltd, Taicang, Peoples R China
[4] Connect Biopharm LLC, San Diego, CA USA
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2024年 / 191卷
关键词：
moderate-to-severe atopic dermatitis; rademikibart; CBP-201; therapy; IL-4R alpha;
D O I：
10.1093/bjd/ljae266.086
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
712
引用
收藏
页数：2
相关论文
共 32 条
  • [1] Dupilumab prevents flares in adults with moderate-to-severe atopic dermatitis in a 52-week, randomized, controlled, phase 3 trial
    Merola, J. F.
    Sidbury, R.
    Wollenberg, A.
    Chen, Z.
    Zhang, A.
    Shumel, B.
    Rossi, A. B.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2020, 140 (07) : S53 - S53
  • [2] Effectiveness and safety of upadacitinib for moderate-to-severe atopic dermatitis in a real-world setting: A 52-week retrospective study
    Gargiulo, L.
    Ibba, L.
    Piscazzi, F.
    Alfano, A.
    Ingurgio, R. Cascio
    Valenti, M.
    Costanzo, A.
    Narcisi, A.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2024, 38 (02) : e152 - e154
  • [3] Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study
    Paller, Amy S.
    Flohr, Carsten
    Eichenfield, Lawrence F. F.
    Irvine, Alan D. D.
    Weisman, Jamie
    Soung, Jennifer
    Correia, Ana Pinto
    Natalie, Chitra R. R.
    Capriles, Claudia Rodriguez
    Pierce, Evangeline
    Reifeis, Sarah
    Lima, Renata Gontijo
    Tubau, Clara Armengol
    Laquer, Vivian
    Weidinger, Stephan
    DERMATOLOGY AND THERAPY, 2023, 13 (07) : 1517 - 1534
  • [4] Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study
    Amy S. Paller
    Carsten Flohr
    Lawrence F. Eichenfield
    Alan D. Irvine
    Jamie Weisman
    Jennifer Soung
    Ana Pinto Correia
    Chitra R. Natalie
    Claudia Rodriguez Capriles
    Evangeline Pierce
    Sarah Reifeis
    Renata Gontijo Lima
    Clara Armengol Tubau
    Vivian Laquer
    Stephan Weidinger
    Dermatology and Therapy, 2023, 13 (7) : 1517 - 1534
  • [5] A 52-week update of a multicentre Italian real-world experience on effectiveness and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis
    Stingeni, Luca
    Bianchi, Leonardo
    Antonelli, Elettra
    Caroppo, Elena Sofia
    Ferrucci, Silvia Mariel
    Gurioli, Carlotta
    Ortoncelli, Michela
    Fabbrocini, Gabriella
    Nettis, Eustachio
    Schena, Donatella
    Napolitano, Maddalena
    Gola, Massimo
    Bonzano, Laura
    Rossi, MariaTeresa
    Belloni Fortina, Anna
    Balato, Anna
    Peris, Ketty
    Foti, Caterina
    Guarneri, Fabrizio
    Romanelli, Marco
    Patruno, Cataldo
    Savoia, Paola
    Esposito, Maria
    Russo, Filomena
    Errichetti, Enzo
    Bianchelli, Tommaso
    Bianchi, Luca
    Pellacani, Giovanni
    Feliciani, Claudio
    Offidani, Annamaria
    Corazza, Monica
    Micali, Giuseppe
    Milanesi, Nicola
    Malara, Giovanna
    Chiricozzi, Andrea
    Tramontana, Marta
    Hansel, Katharina
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2023, 37 (03) : E384 - E388
  • [6] Long-term efficacy and safety of stapokibart for moderate-to-severe atopic dermatitis: 52-week results from a phase 3 trial
    Zhao, Yan
    Zhang, Litao
    Wu, Liming
    Yang, Bin
    Wang, Jinyan
    Li, Yumei
    Li, Jingyi
    Diao, Qingchun
    Sun, Qing
    Zhu, Xiaohong
    Man, Xiaoyong
    Wang, Lihua
    Li, Linfeng
    Feng, Yanyan
    Zeng, Huiming
    Cai, Tao
    Ren, Hong
    Lu, Jianyun
    Lu, Qianjin
    Tao, Xiaohua
    Xiao, Rong
    Ji, Chao
    Li, Fuqiu
    Zhang, Jianzhong
    ALLERGY, 2024,
  • [7] Upadacitinib 30 mg for the optimal management of moderate-to-severe atopic dermatitis: a 52-week single-center real-world study
    Gargiulo, Luigi
    Ibba, Luciano
    Bianco, Matteo
    Di Giulio, Sara
    Alfano, Alfano
    Ingurgio, Ruggero Cascio
    Facheris, Paola
    Perugini, Chiara
    Valenti, Mario
    Costanzo, Antonio
    Narcisi, Alessandra
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2024, 35 (01)
  • [8] QUALITY OF LIFE AND TREATMENT SATISFACTION WITH TILDRAKIZUMAB IN MODERATE-TO-SEVERE PSORIASIS PATIENTS: 52-WEEK INTERIM DATA OF THE REAL-WORLD POSITIVE STUDY
    Augustin, Matthias
    Sommer, Raquel
    Reguiai, Ziad
    Gerdes, Sascha
    Dauden, Esteban
    Weger, Wolfgang
    Maul, Julia-Tatjana
    Laws, Philip
    Naldi, Luigi
    Ghislain, Pierre-Dominique
    de Jong, Elke
    Mburu, Sicily
    Koscielny, Volker
    Massana, Eric
    Kasujee, Ismail
    Mrowietz, Ulrich
    ACTA DERMATO-VENEREOLOGICA, 2024, 104
  • [9] Long-term, observational, real-world study of dupilumab for the treatment of moderate-to-severe atopic dermatitis: a 52-week single-center retrospective analysis in China
    Deng, Sisi
    Wang, Huan
    Chen, Qiquan
    Chen, Xueqin
    Song, Xiao
    Chen, Shuguang
    Kong, Minmin
    Song, Zhiqiang
    ARCHIVES OF DERMATOLOGICAL RESEARCH, 2024, 316 (06)
  • [10] EFFECTIVENESS AND SAFETY OF TILDRAKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS LOCATED IN SPECIAL AREAS: 52-WEEK RESULTS FROM THE POSITIVE STUDY
    Sommer, Rachel
    Augustin, Matthias
    Reguiai, Ziad
    Gerdes, Sascha
    Dauden, Esteban
    Weger, Wolfgang
    Maul, Julia-Tatjana
    Laws, Philip
    Naldi, Luigi
    Ghislain, Pierre -Dominique
    de Jong, Elke
    Mburu, Sicily
    Koscielny, Volker
    Massana, Eric
    Kasujee, Ismail
    Mrowietz, Ulrich
    ACTA DERMATO-VENEREOLOGICA, 2024, 104
1234